Key features and details
- PE Mouse monoclonal [GHI/75] to LILRB1, prediluted
- Suitable for: Flow Cyt
- Reacts with: Human
- Conjugation: PE. Ex: 488nm, Em: 575nm
- Isotype: IgG2b
Product namePE Anti-LILRB1 antibody [GHI/75], prediluted
See all LILRB1 primary antibodies
DescriptionPE Mouse monoclonal [GHI/75] to LILRB1, prediluted
ConjugationPE. Ex: 488nm, Em: 575nm
Tested applicationsSuitable for: Flow Cytmore details
Species reactivityReacts with: Human
Tissue, cells or virus corresponding to Human LILRB1. Hairy cell leukaemia cells.
Database link: Q8NHL6
- Flow Cyt: Human blood cells.
ab186074 recognizes LILRB1, an 110-120 kDa membrane glycoprotein expressed strongly on plasma cells, moderately on circulating B cells, and weakly on monocytes. It is also expressed on T cell and NK cell subsets (variable, individual).
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at +4°C. Store In the Dark.
Storage bufferpH: 7.4
Preservative: 0.097% Sodium azide
Constituents: 0.2% BSA, 99% PBS
Concentration information loading...
Our Abpromise guarantee covers the use of ab186074 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Flow Cyt||Use at an assay dependent concentration.
10 μl reagent / 100 μl of whole blood or 106 cells in a suspension.
FunctionReceptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles. Receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response. Engagement of LILRB1 present on natural killer cells or T-cells by class I MHC molecules protects the target cells from lysis. Interaction with HLA-B or HLA-E leads to inhibition of the signal triggered by FCER1A and inhibits serotonin release. Inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.
Tissue specificityExpressed predominantly on B-cells and monocytes, and at lower levels on dendritic cells. Detected on a low percentage of T-cells and natural killer (NK) cells.
Sequence similaritiesContains 4 Ig-like C2-type (immunoglobulin-like) domains.
DomainContains 4 copies of a cytoplasmic motif that is referred to as the immunoreceptor tyrosine-based inhibitor motif (ITIM). This motif is involved in modulation of cellular responses. The phosphorylated ITIM motif can bind the SH2 domain of several SH2-containing phosphatases.
modificationsPhosphorylated on tyrosine residues. Dephosphorylated by PTPN6.
- Information by UniProt
- CD85 antibody
- CD85 antigen antibody
- CD85 antigen like family member J antibody
ab186074 has not yet been referenced specifically in any publications.